Kornimate/medical-research-clean huggingface dataset:
effect of external electrical stimulation and pelvic floor muscle training

Conditions: Urinary Incontinence, Stress; Electrical Stimulation; Pelvic Floor Disorders; Urinary Incontinence

Summary: in this study, the effects of the external electrical stimulation (ees) added to pelvic floor muscle training (pfmt) on stress urinary incontinence (sui) were investigated.

fifty one women with mild and moderate sui symptoms were included in the study. the patients were divided into three groups of pfmt (n:17), ees (n:17) and pfmt+ ees (n:17) by block randomization. the pfmt was applied every day of the week, and ees was applied 3 days a week for 8 weeks. pelvic floor muscle strength (pfms), pelvic floor muscle endurance, subjective perception of improvement, severity of incontinence, quality of life, pelvic floor dysfunction (ptd) and urinary parameters were assessed as outcome variables. all measurements, except subjective perception of improvement were investigated before and after treatment.

Eligibility criteria:
inclusion criteria: * having symptoms of pure stress urinary incontinence and stress predominant ui * ability to contract pelvic floor muscle strength * having a mild or moderate sui symptom according to the 24-hour pad test results. exclusion criteria: * pregnancy, * having been treated for incontinence within a period of six months ago, * not being able to cooperate, * presence of urinary infection * use of metal implants or cardiac pacemakers, * epilepsy, * presence of stage 3 or 4 pelvic organ prolapse, * presence of accompanying neurological disease
treatment of coronary in-stent restenosis

Conditions: Restenosis

Summary: the purpose of this study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus.

in-stent restenosis after coronary angioplasty is currently one of the main limitations of this method, leading to a recurrence of exertional angina pectoris or manifesting as acute coronary syndrome. histopathologic substrate of in-stent restenosis is neointimal hyperplasia. repeated plain balloon angioplasty or using cutting balloon catheters in the treatment of in-stent restenosis does not achieve satisfactory results. brachytherapy, used in the past, it has also abandoned. the current treatment of in-stent restenosis is the use of drug eluting stents. local drug released from these stents prevents new neointimal hyperplasia.this treatment carries the risk of late thrombosis (due to delayed neoendotelization) the stent struts and requires rigorous long-term dual antiplatelet therapy with the risk of bleeding complications. the drug-coated balloon catheters provide short-term penetration of the active substance into the vascular wall, leading to the inhibition of hyperproliferation vascular smooth muscle cells, but due to short-term effect they do not affect negatively stent struts neoendotelization. comparable effects of in-stent restenosis therapy using paclitaxel releasing balloons was demonstrated in comparison with paclitaxel releasing stents, however, the development of drug eluting stents meanwhile progressed. the aim of our study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus. primary endpoint of our study is late lumen loss, because it represents accurate angiographic parameter predicting the need for repeat revascularisation and thus the clinical benefit for the patient. the 3rd observational, non-randomised arm compares the treatment with seal-wing paclitaxel-eluting balloon with two randomised arms (peb vs. ees). 3-year long term clinical follow-up of iopromide-coated peb and ees arms was performed. all clinical mace (cv death, ami and tvr) were recorded. subanalysis of seal-wing peb arm comparrng the treatment of bms and des-isr was added.

Eligibility criteria:
inclusion criteria: * history of percutaneous coronary intervention with stent placement * verified coronary in-stent restenosis suitable for percutaneous re-intervention * signed informed consent exclusion criteria: * contraindication to long term dual antiplatelet therapy * increased risk of bleeding * known generalized malignancy * pregnancy

Keywords: coronary artery disease stent restenosis
multicentre study to explore the correlation between smoking pattern and clinical efficacy of epidermal growth factor receptor (egfr) tyrosine kinase inhibitor (tki) in male patients

Conditions: Non Small Cell Lung Cancer

Summary: the objective is to investigate the correlation between smoking pattern and clinical efficacy of egfr tkis in male patients with locally advanced or metastasized non-small cell lung cancer of adeno histology who have failed 1st line chemotherapy. health care resource usage, quality of life (eq-5d) and practice of egfr mutation test will also be evaluated. current practice of egfr mutation testing in taiwan will be surveyed.


Eligibility criteria:
inclusion criteria: * male patients age 20 years or older * histological or cytological confirmation of nsclc of adeno histology. if sputum is the only available sample, a second positive test is necessary for cytological confirmation * locally advanced or metastatic on or after first-line chemotherapy. imaging evidence of disease progression can be either chest x ray, ct or mri assessment on measurable lesions. if no measurable lesion is available, evaluable lesions are acceptable

Keywords: nsclc male smoking pattern efficacy
the spot-hpv study

Conditions: HPV Infection; HPV Positive Oropharyngeal Squamous Cell Carcinoma

Summary: the purpose of this research is to evaluate a new test for oral hpv dna in saliva ('oral rinse test').

this cross-sectional study will characterize the prevalence of salivary ttmv-hpv dna among participants with and without hpv-positive throat cancer oral hpv infection is common among healthy adult men, but most of these infections resolve spontaneously and only a very small percentage of oral hpv infections turn into hpv-positive throat cancer. this study is trying to understand whether this new oral rinse test detects hpv dna from infection, cancer cells, or both. if this test is only positive in people with cancer, it may be useful for diagnosing hpv-positive throat cancer in the future. along with the oral rinse test study participants will complete brief surveys and participants with a positive salivary ttmv-hpv dna tests may have repeat saliva testing, blood tests and head/neck exam. it is expected that about 360 people will take part in this research study. an external laboratory called naveris is supporting this research study by providing testing for hpv dna.

Eligibility criteria:
inclusion criteria: * age 18+ years * able to provide informed consent * either one of the following: * control cohort: male individuals without head and neck tumors that are, or may be, hpv-positive * case cohort: any individual with incident, untreated hpv-positive oropharynx squamous cell carcinoma exclusion criteria: * unable to provide informed consent * head and neck tumors of non-oropharynx subsites that are or may be hpv-positive, including oral cavity, sinonasal, laryngeal, hypopharyngeal, or nasopharyngeal squamous cell carcinomas

Keywords: hpv infection hpv-positive throat cancer
a long-term safety and efficacy study evaluating apg777 in atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multicenter, double-blind, long-term extension (lte) study to evaluate the long-term safety and efficacy of apg777 in patients with moderate-to-severe ad who have completed treatment in an apg777 parent study (nct06395948). the lte study will consist of 3 periods: 1) screening visit will coincide with the last visit of the maintenance period in the parent study 2) extended treatment period 3) post-treatment follow-up period. this study will be conducted in participants with atopic dermatitis (ad) who completed the treatment period in a prior apg777 study and who, in the opinion of the investigator, would benefit from long-term treatment with apg777.


Eligibility criteria:
inclusion criteria: * participants who have completed the treatment period in a prior apg777 study and were, in the investigator's opinion, compliant with the study protocol * participants who, in the investigator's opinion, would benefit from long-term treatment with apg777 * use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the parent study and throughout the lte study exclusion criteria: * participants who have developed an ae while participating in the parent study. which, in the opinion of the investigator or of the medical monitor, could indicate that continued treatment with apg777 may present an unreasonable risk for the patient * participants who terminated early from the parent study or permanently discontinued the study drug during the parent study * use of any of the prohibited medications in the parent study through screening visit (visit 1) of the lte study * presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of ad and/or interfere with study assessments note: additional protocol defined inclusion/exclusion criteria may apply

Keywords: atopic dermatitis apg777 safety efficacy
long term effects of action observation therapy and mirror therapy on upper limb functions

Conditions: Stroke

Summary: there will be a long term effects of action observation therapy and mirror therapy on upper limb functional outcomes after subacute stroke.

however, no study is conducted to check the retention rate of both therapies. my study will check the retention rate of these interventions in stroke. if we are able to know long lasting effects of this particular regime, we can incorporate this cost-effective intervention into our clinical setups for stroke rehabilitation.

Eligibility criteria:
inclusion criteria: * both male and female * 1 to 6 months since unilateral stroke onset * age between 40 and 70 years. * baseline score of the fma motor score between 20 and 40 * ability to follow the study instructions according to montreal cognitive scale and score should be \>24. exclusion criteria: * patients with depression who will be unable to cooperate during treatment and cardiopulmonary diseases which could hinder their ability to participate in rehabilitation * visual and auditory abnormalities * major medical problems or comorbidities that influenced the usage of the upper limbs or caused severe pain.

Keywords: action observation therapy , mirror therapy
see change evaluation - impacts of personal agency training on ugandan entrepreneurs

Conditions: Well-Being, Psychological; Economic Hardship; Stress

Summary: this study is proposed as an individually randomized control trial (rct) designed to assess the short-term impacts (follow up at six months) of a personal agency training on a range of economic and health outcomes for micro and small entrepreneurs in western and central uganda. participants will be randomly selected and assigned to either the intervention group (n=400) or wait-listed control group (n=400). the intervention will include the standard empowered entrepreneur training curriculum which includes personal agency alongside basic business training that has been developed by the see change team. this training will take place over three consecutive days (approximately 25 hours of content).

the investigators propose to examine the comparative impacts of a personal agency and business training curricula on outcome measures focused in three areas 1) business related outcomes; 2) personal agency and flourishing; and 3) social spillover impacts. aim 1: assess changes in business related outcomes including improved sales and profit, enhanced business skills and behaviors, and business-related goal setting. aim 2: assess changes in personal agency and flourishing as determined through personal goal setting and psychometric measurements of self-esteem, self-confidence, grit and flourishing. aim 3: assess social spillover impacts of the training on depression, anxiety and stress, and changes in gender norms and attitudes.

Eligibility criteria:
inclusion criteria: * small or micro entrepreneur; * business has been in operation/existence for at least the past 12 months; * entrepreneur is between the ages of 18 and 55; * entrepreneur has the ability to participate in all training activities; * informed consent is obtained from the entrepreneur; * the entrepreneur is not planning to leave the area in the next 12 months; * the entrepreneur has access to a phone for contact purposes; exclusion criteria: * entrepreneur is unable to provide informed consent or informed consent is not obtained; * entrepreneur is not considered a small or micro entrepreneur; * entrepreneur is younger than 18 years of age; * business has been in operation/existence for less than 12 months; * entrepreneur's primary business is farming (anything related to seasonal crop production); * entrepreneur is planning to leave the area in the next 12 months;

Keywords: personal agency entrepreneurship flourishing
comparison of the risk of venous thromboembolism (i.e., blood clots in the veins) and bleeding events in a population of obese patients receiving higher-dose or extended-duration versus conventional-dose or conventional-duration of prophylaxis (i.e., preventive treatment) with enoxaparin

Conditions: Venous Thromboembolism

Summary: in individuals with obesity, the optimal dosing and duration of venous thromboembolism (vte) prophylaxis in settings representing acute medical illness or surgery is limited due to lack of randomized controlled trials (rcts) focusing specifically on this population. evidence suggests that in obese participants, both higher dosing and duration of vte prophylaxis with low molecular weight heparins (lmwh) may be required to achieve a therapeutic effect similar to non-obese participants. this non-interventional study utilizes data already collected from a usual clinical practice setting in the optum us clinical database, representing obese participants hospitalized with an acute medical condition or undergoing surgery receiving enoxaparin prophylaxis. its aim is to compare the impact of the following enoxaparin prophylaxis strategies on the incidence of symptomatic vte and major bleeding in the overall study population and prespecified subgroups: * high versus conventional dose * extended versus conventional duration * combined high-dose and extended-duration versus conventional-dose and conventional-duration. the first date of enoxaparin prophylaxis will be the index date.

the study period will be from february 2010 to september 2021. participants will be followed for 90 days.

Eligibility criteria:
inclusion criteria: * medical patients: hospitalization due to: * heart failure * ischemic stroke * respiratory insufficiency * infection * inflammatory diseases * active cancer * surgical patents: following surgery types: * orthopedic * thoracic * abdominal/pelvic * other inclusion criteria: * initiation of enoxaparin prophylaxis (index date) * age ≥ 40 years * body mass index (bmi) ≥ 30 exclusion criteria: * vte or bleeding event during or 3 months prior to index date * surgery within 3 months prior to and up to two days following index date * atrial fibrillation * antiplatelet or anticoagulation therapy within \[-32, -2\] days before index date * chronic kidney disease (ckd) stages iv and v, or dialysis * pregnancy the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
estradiol and progesterone levels following frozen embryo transfer

Conditions: Infertility

Summary: the aim of the present study is to investigate serum estradiol and progesterone levels in women conceiving after natural, estradiol + progesterone or gonadotropin stimulated frozen embryo transfer (fet) cycles.

enrolled women will be randomized based on their ovulation pattern. ovulatory women will be randomized to either natural cycle or estradiol + progesterone substituted cycle treatment for fet. anovulatory women will be randomized to either estradiol + progesterone substituted cycle or gonadotropin stimulated cycle treatment for fet. included women will undergo blood testing every two weeks for serum estradiol and progesterone levels until gestational age 9+6. routine vaginal ultrasounds will be performed as well as additional pregnancy ultrasounds. secondary obstetric outcomes will be investigated using the womens medical journals. all the treatments are considered standard treatments for fet.

Eligibility criteria:
inclusion criteria: * age \> 18 years \< 40 years * bmi \< 35 kg/m2 * normal wet smear within the past three years * thawed blastocysts (day 5 or 6) after either ivf or icsi treatment exclusion criteria: * age \< 18 years * bmi \> 35 kg/m2 * oocyte donation * hiv/ hepatitis * undiagnosed vaginal bleeding * uterine malformations * persisting ovarian cysts * tumors in hypothalamus, pituitary, thyroid or adrenal * previous breast cancer * brca1/2 * unregulated thyroid disease * cardiovascular disease * breast feeding * present or previous chemotherapy/radiation therapy * present or previous malignant disease * smoking * alcohol/drug abuse
young women's health coop (cooperative) in cape town

Conditions: HIV; Substance Abuse

Summary: this supplement study is an adaptation of the larger nih-funded parent study, the women's health coop+, which tests a combination biobehavioral hiv prevention approach to enhance standard hiv testing practices for alcohol and drug (aod)-using women across the city of pretoria, south africa. the current supplemental study seeks to reach aod-using female adolescents who experience the greatest burden of new hiv infections and are currently underserved by hiv and drug-treatment programs in cape town, south africa and test the validation of both the instrument and adapted intervention.

this study is testing and validating both the revised instrument and adapted intervention through a small pilot trial where a cluster randomized design is used to recruit 100 participants through snowball sampling by community to either the ywhc condition or standard hiv counseling and testing (hct); collect biological specimens to screen for recent drug use, pregnancy and hiv infection and provide referrals for care to resources; conduct process evaluation measures for satisfaction and a 1-month follow-up post-intervention interview assessing the feasibility and preliminary efficacy of conducting this intervention among vulnerable young women and linking them to care. young women from disadvantaged communities in cape town who have dropped out of school and who use aods are highly vulnerable to physical victimization (violence and sexual victimization) from any perpetrator, including main sexual partners and drug-related sexual risks for hiv. yet these vulnerable young women remain underserved by current hiv and drug treatment programs in the region, even though they are experiencing the greatest burden of new hiv infections in the country. the adapted young women's health coop (ywhc) intervention has a high likelihood of wider implementation, sustainability, and a significant public health impact by reducing the exceedingly high hiv incidence amongst the most vulnerable populations in south africa.

Eligibility criteria:
inclusion criteria: * female, 16 to 21 years of age * dropped out of school for at least 6 months * currently dropped out of school * have not completed matric or n 3 certificate * have used at least one drug (which can include alcohol) at least weekly in the past 90 days * report unprotected sex with a male partner in the last 90 days * able to provide informed assent to participate or informed consent if at least 18 years old * live in a targeted community delft, khayelitsha, or mfuleni exclusion criteria: • have been a part of formative activities

Keywords: hiv sexual risk sexually transmitted diseases substance abuse violence and victimization
safety and efficacy study with allergen extracts of house dust mites for specific sublingual immunotherapy

Conditions: Allergic Rhinitis

Summary: the objective of this clinical trial is to assess the safety and efficacy of sublingual application of allergen extracts for specific immunotherapy in patients suffering from perennial allergic rhinitis due to house dust mites.


Eligibility criteria:
inclusion criteria: * positive history of perennial allergic rhinitis * positive screening skin prick test (wheal diameter \> 3 mm) * compliance and ability of the patient to complete a diary card for self-evaluating of the symptoms and antisymptomatic medication * signed and dated patient´s informed consent, exclusion criteria: * previous immunotherapy with allergen extracts within the last 3 years, * simultaneous participation in other clinical trials, * other reasons contra-indicating an inclusion into the trial according to the investigator´s estimation (e.g. poor compliance), * auto-immune disorders, * severe chronic inflammatory diseases, * malignancy, * alcohol abuse, * existing or intended pregnancy, lactation and/or lack of adequate contraceptive protection, * treatment with beta-blockers (incl. local application) and/or other contra-indicated drugs.
the effectiveness of trans-catheter foam sclerotherapy of pelvic and atypical lower limb varicosities

Conditions: Venous Insufficiency

Summary: pelvic congestion is the most recognized consequence of pelvi-perineal venous insufficiency . chronic pelvic pain prevalence is about 26.6 %in egypt. this research is going to evaluate the effectiveness of foam sclerotherapy and to conclude diagnostic and therapeutic algorithm for this problem.

this study includes clinical and imaging and interventional aspects. detailed history and comprehensive examination of the patient. duplex ultrasonography to detect pelvic varices and presence of reflux. renal and left iliac venogram is usually the first step in the evaluation of compressive syndrome. then cannulate the gonadal and internal iliac veins selectively. contrast medium injected , the incompetent gonadal veins are generally dilated and the contrast pools in the pelvis after injection. embolization by injecting afoam sclerosant as distally as possible to occlude the pelvic venous plexus using occlusion balloon proximal. follow up assessment by vas score and duplex imaging.

Eligibility criteria:
inclusion criteria: * premenopausal women ovarian point tenderness post coital pain atypical lower limb varices exclusion criteria: * endometriosis diverticulitis fasciitis psychosexual dysfunction